These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38735245)

  • 1. The landscape of angiogenesis and inflammatory factors in eyes with myopic choroidal neovascularization before and after anti-VEGF injection.
    Wang T; Lian P; Zhan J; Li Y; Liu B; Zhao X; Wu Q; Li H; Lu L; Chen S
    Cytokine; 2024 Jul; 179():156640. PubMed ID: 38735245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of inflammatory cytokines with choroidal neovascularization in highly myopic eyes.
    Yamamoto Y; Miyazaki D; Sasaki S; Miyake K; Kaneda S; Ikeda Y; Baba T; Yamasaki A; Noguchi Y; Inoue Y
    Retina; 2015 Feb; 35(2):344-50. PubMed ID: 25289657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization.
    Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
    Acta Ophthalmol; 2011 Aug; 89(5):459-62. PubMed ID: 20102348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C; Semeraro F; dell'Omo R; Romano MR; Russo A; Aceto F; Mastropasqua R; Porcellini A
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of anti-vascular endothelial growth factor therapy with and without posterior scleral reinforcement on myopic maculopathy in myopic choroidal neovascularization eyes.
    Kang MT; Wang N; Xu W; Yusufu M; Liu W; Tian J; Qi Y
    BMC Ophthalmol; 2024 Mar; 24(1):118. PubMed ID: 38481176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization.
    Di Antonio L; Toto L; Mastropasqua A; Brescia L; Erroi E; Lamolinara A; Di Nicola M; Mastropasqua L
    Sci Rep; 2018 Oct; 8(1):15631. PubMed ID: 30353107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of immunological factors in the development of myopic choroidal neovascularization].
    Shchuko AG; Zaytseva NV; Yur'eva TN; Chernykh ER; Mikhalevich IM; Grigor'eva AV
    Vestn Oftalmol; 2016; 132(5):5-14. PubMed ID: 27911420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment.
    Bae KW; Kim DI; Kim BH; Oh BL; Lee EK; Yoon CK; Park UC
    PLoS One; 2022; 17(9):e0273613. PubMed ID: 36137056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.
    Coelho J; Ferreira A; Abreu AC; Monteiro S; Furtado MJ; Gomes M; Lume M
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2679-2686. PubMed ID: 33744983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in aqueous concentration and vitreous mass of cytokines in high myopias with and without choroidal neovascularization.
    Zhang S; Mao J; Chen N; Fang Y; Chen Y; Zheng Z; Chen Y; Shen L
    Front Med (Lausanne); 2022; 9():1029425. PubMed ID: 36438065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
    Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
    Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.
    Teo KY; Ng WY; Lee SY; Cheung CM
    Drugs; 2016 Jul; 76(11):1119-33. PubMed ID: 27364753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization.
    Ahn SJ; Woo SJ; Kim KE; Park KH
    Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2115-22. PubMed ID: 23462751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation.
    Xiao H; Zhao X; Li S; Sun L; Xin W; Wang Z; Zhang A; Zhang J; Ding X
    Br J Ophthalmol; 2021 Jan; 105(1):103-108. PubMed ID: 32161005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular Cytokines and Their Correlations with Clinical Parameters in Patients with Myopic Choroidal Neovascularization.
    Shchuko AG; Zaitseva NV; Yurieva TN; Chernykh ER; Mikhalevich IM; Shevela EY; Grigorieva AV
    Ophthalmologica; 2017; 237(2):96-104. PubMed ID: 28103602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
    Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
    Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
    Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF Therapy in Myopic CNV.
    Toto L; Di Antonio L; Costantino O; Mastropasqua R
    Curr Drug Targets; 2021; 22(9):1054-1063. PubMed ID: 33511955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.